Trial Profile

A first-in-human, open-label, dose-escalation Phase 1 clinical trial of APTN-101 program in glioblastoma (GBM)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APTN 101 (Primary)
Indications Glioblastoma; Glioma
Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

20 Aug 2026 Status changed from planning to recruiting, according to an Adaptin Bio media release.
14 May 2026 According to an Adaptin Bio media release, trial to begin shortly.
20 Jan 2026 According to an Adaptin Bio media release, company announced that the Preston Robert Tisch Brain Tumor Center has granted the first Institutional Review Board (IRB) approval for its Phase 1 first-in-human clinical trial evaluating APTN-101 in the treatment of glioblastoma multiforme (GBM).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com